{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-024705","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.736219+00:00","generated_at":"2026-05-17T21:16:49.411229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Azenta Q3 revenue flat at $144M; non-GAAP EPS $0.19 vs $0.14 YoY; reaffirms FY2025 guidance","bullets":["Revenue $144M flat YoY; organic revenue down 2%. Sample Management Solutions -4%, Multiomics +4%.","Non-GAAP diluted EPS $0.19 (vs $0.14); GAAP EPS from cont ops $0.01 (vs ($0.00)).","Adjusted EBITDA $18M, margin 12.3% (+260 bps); operating cash flow $26M, FCF $15M.","FY2025 guidance reaffirmed: organic growth 3-5% and ~300 bps EBITDA margin expansion.","Discontinued ops (B Medical) $50M non-cash impairment; total diluted EPS ($1.15)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-024705","json":"https://secwatch.observer/filing/0001437749-25-024705.json","markdown":"https://secwatch.observer/filing/0001437749-25-024705.md","text":"https://secwatch.observer/filing/0001437749-25-024705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000143774925024705/0001437749-25-024705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000143774925024705/azta20250514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:16:49.411229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}